<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02877264</url>
  </required_header>
  <id_info>
    <org_study_id>BTA798-104</org_study_id>
    <nct_id>NCT02877264</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Single-Center, Open-Label, Three-Period, Six-Sequence, Crossover, Comparative Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Product Formulations in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aviragen Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaxart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single-center, open-label, three-period, six-sequence, crossover,&#xD;
      comparative study to evaluate the oral bioavailability of single doses of three vapendavir&#xD;
      drug product formulations (the 264 mg free base tablet [test drug], 264 mg free base oral&#xD;
      suspension [test drug], and two 132 mg phosphate salt capsules [reference drug]) in healthy&#xD;
      volunteers. The study design consists of six dosing sequences. Each sequence comprises 3&#xD;
      periods and each subject is administered one of the three dosing formulations in the first&#xD;
      period. A subject receives a different formulation in each of the subsequent periods, so that&#xD;
      all subjects receive each formulation. The periods are separated by an approximate 7-day&#xD;
      washout.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Owner of Study Record: Vaxart Inc.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative oral bioavailability, as applicable</measure>
    <time_frame>Study Day 0 - 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Study Day 0 - 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time at which Cmac was observed (Tmax)</measure>
    <time_frame>Study Day 0 - 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from time ) to the last measureable plasma concentration (AUC 0-last)</measure>
    <time_frame>Study Day 0 - 17</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Vapendavir Capsule, 264 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vapendavir phosphate salt administered orally as a single dose of two 132 mg hard gelatin capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vapendavir Tablets, 264 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vapendavir free base tablets containing 264 mg of vapendavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vapendavir Oral Suspension, 264 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vapendavir free base as a 24 mg/mL oral suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vapendavir 132 mg capsule</intervention_name>
    <arm_group_label>Vapendavir Capsule, 264 mg</arm_group_label>
    <other_name>BTA798</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vapendavir 264 mg tablet</intervention_name>
    <arm_group_label>Vapendavir Tablets, 264 mg</arm_group_label>
    <other_name>BTA798</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vapendavir 24 mg/mL oral suspension</intervention_name>
    <arm_group_label>Vapendavir Oral Suspension, 264 mg</arm_group_label>
    <other_name>BTA798</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be a healthy male or female between 19 and 60 years of age (inclusive) at the&#xD;
             time of signing the informed consent and weigh â‰¥50 kg with a BMI between 18 and 32.0&#xD;
             kg/m2 (inclusive);&#xD;
&#xD;
          2. Capable of giving written informed consent;&#xD;
&#xD;
          3. Subject is able to understand and comply with the protocol requirements, instructions&#xD;
             and restrictions;&#xD;
&#xD;
          4. Healthy on the basis of physical examination, medical history, VS, ECGs, and clinical&#xD;
             laboratory tests;&#xD;
&#xD;
          5. Female subjects who are not postmenopausal for at least 2 years or surgically sterile&#xD;
             with complete hysterectomy or bilateral oophorectomy and male subjects, who are not&#xD;
             surgically sterile via vasectomy, must agree to use a double barrier method of birth&#xD;
             control, such as, a condom plus spermicidal agent (foam/gel/film/cream/suppository)&#xD;
             from Study Day 0 until 30 days after completion of the study. This includes female&#xD;
             subjects who are using hormonal contraception;&#xD;
&#xD;
          6. Female subjects must not be breastfeeding or pregnant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive results at screening for hepatitis B, hepatitis C, or HIV;&#xD;
&#xD;
          2. No use of tobacco products, as well as electronic cigarettes, within 14 days of Study&#xD;
             Day 1 or unwilling to abstain during study participation;&#xD;
&#xD;
          3. A medical history or clinical evidence of any clinical condition that may, in the&#xD;
             opinion of the Investigator or Medical Monitor, impact on the subject's ability to&#xD;
             participate in the study, or on the study results;&#xD;
&#xD;
          4. Current or recent respiratory or other infection within 14 days of screening;&#xD;
&#xD;
          5. Presence or history of significant allergy requiring treatment;&#xD;
&#xD;
          6. Clinically significant abnormalities on ECG;&#xD;
&#xD;
          7. Vital signs representing abnormal systolic blood pressure and/or abnormal diastolic&#xD;
             blood pressure;&#xD;
&#xD;
          8. Safety laboratory abnormalities at screening or Study Day 0 which are clinically&#xD;
             significant;&#xD;
&#xD;
          9. Subject has a history of drug abuse or alcohol abuse in the past 2 years or current&#xD;
             evidence of such abuse or addiction;&#xD;
&#xD;
         10. A positive urine drug screen test at screening or admission to the study facility;&#xD;
&#xD;
         11. A positive breathalyzer for alcohol at screening or admission to the study facility;&#xD;
&#xD;
         12. A positive pregnancy test at screening or admission to the study facility;&#xD;
&#xD;
         13. Abstinence from alcohol must be employed from 72 hours before Study Day 1 and&#xD;
             throughout the duration of study participation;&#xD;
&#xD;
         14. Use of chronic prescription medications within 90 days, with the exception of hormonal&#xD;
             contraceptives (or contraceptive device containing hormonal contraceptive) being taken&#xD;
             by female subjects within 14 days, or over-the-counter (OTC) medications, including&#xD;
             vitamin, herbal, and mineral supplements, within the 7 days prior to Study Day 1 and&#xD;
             throughout study participation;&#xD;
&#xD;
         15. Received an investigational drug or investigational vaccine within 30 days, or use of&#xD;
             an investigational medical device within 30 days prior to Study Day 1;&#xD;
&#xD;
         16. Any prior use of vapendavir or inclusion in a previous vapendavir investigational&#xD;
             study or ongoing participation in a vapendavir investigational study;&#xD;
&#xD;
         17. Donation or loss of whole blood within 60 days or plasma within 14 days of Study Day 1&#xD;
             or anytime from screening to 30 days after completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Novotney-Barry</last_name>
    <role>Study Director</role>
    <affiliation>Aviragen Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aviragen Investigational Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2016</study_first_posted>
  <last_update_submitted>November 21, 2018</last_update_submitted>
  <last_update_submitted_qc>November 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vapendavir</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Biological Availability</keyword>
  <keyword>Volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

